PDMR Dealing/Issue of Equity
Cambridge, UK and Indianapolis, US – 1 October 2019: Acacia Pharma Group plc (the "Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission in aggregate of 303,841 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. This includes options exercised by Dr Gabriel Fox (Chief Medical Officer and PDMR) to subscribe for 168,651 Ordinary Shares of £0.02 each in the Company at an exercise price of £0.15 each.
Following the exercise of these options, Dr Fox holds 497,227 Ordinary Shares, representing approximately 0.92% of the Company's enlarged issued share capital. Dr Fox holds 52,631 of these shares through Comedica Consulting Limited, a company wholly owned by him.
The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.
Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,938,756 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,938,756.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Dr Gabriel Fox |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Medical Officer/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Acacia Pharma Group plc |
| b) | LEI | 213800SLDKXWKT6E3381 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.02 each GB00BYWF9Y76 |
| b) | Nature of the transaction | Share options exercise |
| c) | Price(s) and volume(s) | 168,651 Ordinary Shares at a price of £0.15 pence per share |
| d) | Aggregated information - Aggregated volume - Price |
N/A |
| e) | Date of the transaction | 30 September 2019 |
| f) | Place of the transaction | Euronext Brussels (XBRU) |
Contacts
| Acacia Pharma Group plc Michael Bolinder, CEO Christine Soden, CFO |
+44 1223 919760 |
| Citigate Dewe Rogerson Mark Swallow, Shabnam Bashir, David Dible |
+44 20 7638 9571 |